J.W. Cole Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-12,600
| Closed | -$64K | – | 897 |
|
|
2024
Q1 | $64K | Sell |
12,600
-7,500
| -37% | -$38.1K | ﹤0.01% | 869 |
|
|
2023
Q4 | $120K | Buy |
20,100
+200
| +1% | +$1.2K | 0.01% | 788 |
|
|
2023
Q3 | $141K | Sell |
19,900
-2,300
| -10% | -$16.3K | 0.01% | 699 |
|
|
2023
Q2 | $156K | Hold |
22,200
| – | – | 0.01% | 716 |
|
|
2023
Q1 | $185K | Hold |
22,200
| – | – | 0.01% | 731 |
|
|
2022
Q4 | $255K | Hold |
22,200
| – | – | 0.02% | 620 |
|
|
2022
Q3 | $280K | Sell |
22,200
-100
| -0.4% | -$1.26K | 0.02% | 564 |
|
|
2022
Q2 | $236K | Sell |
22,300
-8,500
| -28% | -$90K | 0.02% | 619 |
|
|
2022
Q1 | $501K | Sell |
30,800
-6,000
| -16% | -$97.6K | 0.03% | 453 |
|
|
2021
Q4 | $510K | Buy |
36,800
+735
| +2% | +$10.2K | 0.03% | 455 |
|
|
2021
Q3 | $547K | Buy |
36,065
+15,665
| +77% | +$238K | 0.04% | 239 |
|
|
2021
Q2 | $323K | Sell |
20,400
-2,000
| -9% | -$31.7K | 0.03% | 561 |
|
|
2021
Q1 | $228K | Hold |
22,400
| – | – | 0.02% | 592 |
|
|
2020
Q4 | $167K | Buy |
+22,400
| New | +$167K | 0.02% | 604 |
|